Bezafibrate has emerged as a significant therapeutic agent for improving transplant-free survival in patients with primary biliary cholangitis (PBC) when used in combination with ursodeoxycholic acid (UDCA). PBC is a chronic autoimmune liver disease that can progress to cirrhosis and liver failure, necessitating liver transplantation.
Bezafibrate has emerged as a significant therapeutic agent for improving transplant-free survival in patients with primary biliary cholangitis (PBC) when used in combination with ursodeoxycholic acid (UDCA). PBC is a chronic autoimmune liver disease that can progress to cirrhosis and liver failure, necessitating liver transplantation. While UDCA remains the first-line treatment, a subset of patients exhibits incomplete biochemical responses, requiring additional therapeutic interventions.
Recent real-world evidence from a large Japanese cohort study, encompassing 3,908 patients and over 21,000 patient-years, demonstrated that the combination of bezafibrate (BZF) and UDCA substantially improved long-term outcomes. Patients receiving UDCA + BZF experienced a marked reduction in the risk of all-cause mortality and liver-related death or transplantation, with adjusted hazard ratios of 0.33 and 0.27, respectively, both highly significant (p < 0.001). This survival benefit was consistent across various baseline risk groups, underscoring the robustness of the findings.
The clinical benefit of the combination therapy was quantified through the number needed to treat (NNT). To prevent one additional death or liver transplantation, the NNT was 29 at 5 years, 14 at 10 years, and 8 at 15 years, highlighting its substantial long-term efficacy. Importantly, bezafibrate not only improves biochemical markers and symptoms, as shown in prior trials, but also enhances survival outcomes, reinforcing its role as a second-line treatment for PBC.
These findings strongly support the routine use of bezafibrate alongside UDCA in patients with incomplete response, offering a promising strategy to improve transplant-free survival and overall disease management in PBC.
Introduction: Acute kidney injury (AKI) is a frequent and life-threatening complication of cirrhosis, with management often complicated by inaccurate assessment of intravascular volume and the presence of cirrhotic cardiomyopathy (CCM). This prospective study evaluated whether...
Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...
Introduction: Adults with Fontan-type circulation are increasingly recognized to develop Fontan-associated liver disease and portal hypertension. This prospective study explored the prevalence, anatomical distribution, and hemodynamic characteristics of esophageal varices (EV), with particular emphasis on...
Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...
Introduction: Despite advances in the management of portal hypertension, mortality after variceal bleeding remains high in patients with cirrhosis. Experimental and clinical studies suggest that statins may improve portal hypertension and hepatic vascular function. This...
Introduction: Acute liver failure (ALF) complicated by cerebral oedema carries a high risk of early mortality, primarily due to hyperammonemia and intracranial hypertension. The optimal timing of continuous renal replacement therapy (CRRT) in these critically...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.